Roth Capital Resumes BioLineRx (BLRX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Roth Reinstates BioLineRx (BLRX) at 'Buy'; Strong Pipeline Reinforces Upside Potential
July 2, 2014 9:27 AM EDTRoth Capital reinstates BioLineRx Ltd. (Nasdaq: BLRX) with a Buy rating and price target of $8.
Analust Joseph Pantginis issued the following commentary with the reinstatement, We believe BioLineRx is poised for growth based on a deep pipeline, risk mitigation through its early partnering business model, and partnering validation based on multiple partnerships already in hand. We believe BioLineRx has the ability to maintain a... More
